Mylan sues Celgene for blocking access to Revlimid, Thalomid

Generics company Mylan Inc. (NASDAQ:MYL) filed suit in the U.S. District Court for the District of New Jersey alleging that Celgene Corp. (NASDAQ:CELG) is violating antitrust laws by preventing Mylan from obtaining samples of cancer drugs Thalomid thalidomide and Revlimid lenalidomide. Mylan, which is developing generic versions of the drugs, said Celgene is using its restricted distribution REMS programs for the drugs as a pretext to prevent Mylan from obtaining samples to conduct required bioequivalence studies. Mylan is asking the court to compel Celgene to sell Mylan sufficient quantities of Revlimid and Thalomid for testing, plus damages. ...